001package org.hl7.fhir.dstu3.model.codesystems; 002 003/* 004 Copyright (c) 2011+, HL7, Inc. 005 All rights reserved. 006 007 Redistribution and use in source and binary forms, with or without modification, 008 are permitted provided that the following conditions are met: 009 010 * Redistributions of source code must retain the above copyright notice, this 011 list of conditions and the following disclaimer. 012 * Redistributions in binary form must reproduce the above copyright notice, 013 this list of conditions and the following disclaimer in the documentation 014 and/or other materials provided with the distribution. 015 * Neither the name of HL7 nor the names of its contributors may be used to 016 endorse or promote products derived from this software without specific 017 prior written permission. 018 019 THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND 020 ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED 021 WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. 022 IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, 023 INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT 024 NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR 025 PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, 026 WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) 027 ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE 028 POSSIBILITY OF SUCH DAMAGE. 029 030*/ 031 032// Generated on Mon, Apr 17, 2017 17:38-0400 for FHIR v3.0.1 033 034 035import org.hl7.fhir.exceptions.FHIRException; 036 037public enum V3ObservationInterpretation { 038 039 /** 040 * Codes that specify interpretation of genetic analysis, such as "positive", "negative", "carrier", "responsive", etc. 041 */ 042 _GENETICOBSERVATIONINTERPRETATION, 043 /** 044 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 045 */ 046 CAR, 047 /** 048 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 049 050 051 052 Deprecation Comment: 053 This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code "Carrier" and to add "CAR" as the new active code representation for this concept. 054 */ 055 CARRIER, 056 /** 057 * Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed. 058 */ 059 _OBSERVATIONINTERPRETATIONCHANGE, 060 /** 061 * The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure). 062 063 [Note: This can be applied to quantitative or qualitative observations.] 064 */ 065 B, 066 /** 067 * The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). 068 */ 069 D, 070 /** 071 * The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). 072 */ 073 U, 074 /** 075 * The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure). 076 077 [Note: This can be applied to quantitative or qualitative observations.] 078 */ 079 W, 080 /** 081 * Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity. 082 */ 083 _OBSERVATIONINTERPRETATIONEXCEPTIONS, 084 /** 085 * The result is below the minimum detection limit (the test procedure or equipment is the limiting factor). 086 087 Synonyms: Below analytical limit, low off scale. 088 */ 089 LESS_THAN, 090 /** 091 * The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor). 092 093 Synonyms: Above analytical limit, high off scale. 094 */ 095 GREATER_THAN, 096 /** 097 * A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample. 098 099 100 101 Deprecation Comment: 102 This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. 103 */ 104 AC, 105 /** 106 * There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible. 107 108 [Note: A MIC with "IE" and/or a comment may be reported (without an accompanying S, I or R-categorization).] 109 */ 110 IE, 111 /** 112 * A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component. 113 114 115 116 Deprecation Comment: 117 This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. 118 */ 119 QCF, 120 /** 121 * A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture. 122 123 124 125 Deprecation Comment: 126 This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. 127 */ 128 TOX, 129 /** 130 * Interpretation of normality or degree of abnormality (including critical or "alert" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed. 131 */ 132 _OBSERVATIONINTERPRETATIONNORMALITY, 133 /** 134 * The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure). 135 136 [Note: Typically applies to non-numeric results.] 137 */ 138 A, 139 /** 140 * The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 141 142 [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.] 143 */ 144 AA, 145 /** 146 * The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 147 148 Synonym: Above upper panic limits. 149 */ 150 HH, 151 /** 152 * The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 153 154 Synonym: Below lower panic limits. 155 */ 156 LL, 157 /** 158 * The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure). 159 160 Synonym: Above high normal 161 */ 162 H, 163 /** 164 * A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.] 165 166 167 Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for "Very high" in V2 Table 0078 "Interpretation Codes". 168 169 [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead. 170 */ 171 H_, 172 /** 173 * A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician. 174 */ 175 HU, 176 /** 177 * The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure). 178 179 Synonym: Below low normal 180 */ 181 L, 182 /** 183 * A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.] 184 185 186 Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for "Very low" in V2 Table 0078 "Interpretation Codes". 187 188 [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead. 189 */ 190 L_, 191 /** 192 * A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician. 193 */ 194 LU, 195 /** 196 * The result or observation value is within the reference range or expected norm (as defined for the respective test procedure). 197 198 [Note: Applies to numeric or non-numeric results.] 199 */ 200 N, 201 /** 202 * Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed. 203 */ 204 _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY, 205 /** 206 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 207Projects: ISO 20776-1, ISO 20776-2 208 209 [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.] 210 211 [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.] 212 213 [Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.] 214 215 [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 216 */ 217 I, 218 /** 219 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 220 221 222 223 Deprecation Comment: 224 This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). 225 */ 226 MS, 227 /** 228 * A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible. 229 230 NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. 231 232 NOTE 2: For strains yielding results in the "nonsusceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed. 233 234 Synonym: decreased susceptibility. 235 */ 236 NS, 237 /** 238 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure. 239Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 240Projects: ISO 20776-1, ISO 20776-2 241 242 [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.] 243 244 [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 245 */ 246 R, 247 /** 248 * A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. 249 250 251 Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. 252 253 254 Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. 255 */ 256 SYNR, 257 /** 258 * Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success. 259Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 260Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2 261 262 [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.] 263 264 [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 265 */ 266 S, 267 /** 268 * A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates. 269 270 Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition" - page 2. 271 */ 272 SDD, 273 /** 274 * A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. 275 276 277 Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. 278 279 280 Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. 281 */ 282 SYNS, 283 /** 284 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 285 286 287 288 Deprecation Comment: 289 This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). 290 */ 291 VS, 292 /** 293 * The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported. 294 295 296 Example: A positive result on a Hepatitis screening test. 297 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. 298These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. 299Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 300 */ 301 EX, 302 /** 303 * The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported. 304 305 306 Example: A positive result on a Hepatitis screening test. 307 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 308 */ 309 HX, 310 /** 311 * The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported. 312 313 Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3 314 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 315 */ 316 LX, 317 /** 318 * Hold for Medical Review 319 320 321 Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 "Interpretation Codes." 322 */ 323 HM, 324 /** 325 * Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the "meaning" of the quantitative value for the same observation. 326 */ 327 OBSERVATIONINTERPRETATIONDETECTION, 328 /** 329 * The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure. 330 331 332 Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then "indeterminate" (i.e. "cannot be determined") is the appropriate response, not "equivocal". 333 */ 334 IND, 335 /** 336 * The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria. 337 */ 338 E, 339 /** 340 * An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. 341 342 [Note: Negative does not necessarily imply the complete absence of the specified item.] 343 */ 344 NEG, 345 /** 346 * The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure. 347 */ 348 ND, 349 /** 350 * A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. 351 */ 352 POS, 353 /** 354 * The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure. 355 */ 356 DET, 357 /** 358 * Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed. 359 */ 360 OBSERVATIONINTERPRETATIONEXPECTATION, 361 /** 362 * This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Expected" (e.g., presence of drugs in a patient that is taking prescription medication for pain management). 363 */ 364 EXP, 365 /** 366 * This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Unexpected" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management). 367 */ 368 UNE, 369 /** 370 * Interpretation qualifiers in separate OBX segments 371 372 373 Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 "Interpretation Codes." 374 */ 375 OBX, 376 /** 377 * Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test. 378 */ 379 REACTIVITYOBSERVATIONINTERPRETATION, 380 /** 381 * An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent. 382 */ 383 NR, 384 /** 385 * A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test. 386 */ 387 RR, 388 /** 389 * A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test. 390 */ 391 WR, 392 /** 393 * added to help the parsers 394 */ 395 NULL; 396 public static V3ObservationInterpretation fromCode(String codeString) throws FHIRException { 397 if (codeString == null || "".equals(codeString)) 398 return null; 399 if ("_GeneticObservationInterpretation".equals(codeString)) 400 return _GENETICOBSERVATIONINTERPRETATION; 401 if ("CAR".equals(codeString)) 402 return CAR; 403 if ("Carrier".equals(codeString)) 404 return CARRIER; 405 if ("_ObservationInterpretationChange".equals(codeString)) 406 return _OBSERVATIONINTERPRETATIONCHANGE; 407 if ("B".equals(codeString)) 408 return B; 409 if ("D".equals(codeString)) 410 return D; 411 if ("U".equals(codeString)) 412 return U; 413 if ("W".equals(codeString)) 414 return W; 415 if ("_ObservationInterpretationExceptions".equals(codeString)) 416 return _OBSERVATIONINTERPRETATIONEXCEPTIONS; 417 if ("<".equals(codeString)) 418 return LESS_THAN; 419 if (">".equals(codeString)) 420 return GREATER_THAN; 421 if ("AC".equals(codeString)) 422 return AC; 423 if ("IE".equals(codeString)) 424 return IE; 425 if ("QCF".equals(codeString)) 426 return QCF; 427 if ("TOX".equals(codeString)) 428 return TOX; 429 if ("_ObservationInterpretationNormality".equals(codeString)) 430 return _OBSERVATIONINTERPRETATIONNORMALITY; 431 if ("A".equals(codeString)) 432 return A; 433 if ("AA".equals(codeString)) 434 return AA; 435 if ("HH".equals(codeString)) 436 return HH; 437 if ("LL".equals(codeString)) 438 return LL; 439 if ("H".equals(codeString)) 440 return H; 441 if ("H>".equals(codeString)) 442 return H_; 443 if ("HU".equals(codeString)) 444 return HU; 445 if ("L".equals(codeString)) 446 return L; 447 if ("L<".equals(codeString)) 448 return L_; 449 if ("LU".equals(codeString)) 450 return LU; 451 if ("N".equals(codeString)) 452 return N; 453 if ("_ObservationInterpretationSusceptibility".equals(codeString)) 454 return _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY; 455 if ("I".equals(codeString)) 456 return I; 457 if ("MS".equals(codeString)) 458 return MS; 459 if ("NS".equals(codeString)) 460 return NS; 461 if ("R".equals(codeString)) 462 return R; 463 if ("SYN-R".equals(codeString)) 464 return SYNR; 465 if ("S".equals(codeString)) 466 return S; 467 if ("SDD".equals(codeString)) 468 return SDD; 469 if ("SYN-S".equals(codeString)) 470 return SYNS; 471 if ("VS".equals(codeString)) 472 return VS; 473 if ("EX".equals(codeString)) 474 return EX; 475 if ("HX".equals(codeString)) 476 return HX; 477 if ("LX".equals(codeString)) 478 return LX; 479 if ("HM".equals(codeString)) 480 return HM; 481 if ("ObservationInterpretationDetection".equals(codeString)) 482 return OBSERVATIONINTERPRETATIONDETECTION; 483 if ("IND".equals(codeString)) 484 return IND; 485 if ("E".equals(codeString)) 486 return E; 487 if ("NEG".equals(codeString)) 488 return NEG; 489 if ("ND".equals(codeString)) 490 return ND; 491 if ("POS".equals(codeString)) 492 return POS; 493 if ("DET".equals(codeString)) 494 return DET; 495 if ("ObservationInterpretationExpectation".equals(codeString)) 496 return OBSERVATIONINTERPRETATIONEXPECTATION; 497 if ("EXP".equals(codeString)) 498 return EXP; 499 if ("UNE".equals(codeString)) 500 return UNE; 501 if ("OBX".equals(codeString)) 502 return OBX; 503 if ("ReactivityObservationInterpretation".equals(codeString)) 504 return REACTIVITYOBSERVATIONINTERPRETATION; 505 if ("NR".equals(codeString)) 506 return NR; 507 if ("RR".equals(codeString)) 508 return RR; 509 if ("WR".equals(codeString)) 510 return WR; 511 throw new FHIRException("Unknown V3ObservationInterpretation code '"+codeString+"'"); 512 } 513 public String toCode() { 514 switch (this) { 515 case _GENETICOBSERVATIONINTERPRETATION: return "_GeneticObservationInterpretation"; 516 case CAR: return "CAR"; 517 case CARRIER: return "Carrier"; 518 case _OBSERVATIONINTERPRETATIONCHANGE: return "_ObservationInterpretationChange"; 519 case B: return "B"; 520 case D: return "D"; 521 case U: return "U"; 522 case W: return "W"; 523 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "_ObservationInterpretationExceptions"; 524 case LESS_THAN: return "<"; 525 case GREATER_THAN: return ">"; 526 case AC: return "AC"; 527 case IE: return "IE"; 528 case QCF: return "QCF"; 529 case TOX: return "TOX"; 530 case _OBSERVATIONINTERPRETATIONNORMALITY: return "_ObservationInterpretationNormality"; 531 case A: return "A"; 532 case AA: return "AA"; 533 case HH: return "HH"; 534 case LL: return "LL"; 535 case H: return "H"; 536 case H_: return "H>"; 537 case HU: return "HU"; 538 case L: return "L"; 539 case L_: return "L<"; 540 case LU: return "LU"; 541 case N: return "N"; 542 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "_ObservationInterpretationSusceptibility"; 543 case I: return "I"; 544 case MS: return "MS"; 545 case NS: return "NS"; 546 case R: return "R"; 547 case SYNR: return "SYN-R"; 548 case S: return "S"; 549 case SDD: return "SDD"; 550 case SYNS: return "SYN-S"; 551 case VS: return "VS"; 552 case EX: return "EX"; 553 case HX: return "HX"; 554 case LX: return "LX"; 555 case HM: return "HM"; 556 case OBSERVATIONINTERPRETATIONDETECTION: return "ObservationInterpretationDetection"; 557 case IND: return "IND"; 558 case E: return "E"; 559 case NEG: return "NEG"; 560 case ND: return "ND"; 561 case POS: return "POS"; 562 case DET: return "DET"; 563 case OBSERVATIONINTERPRETATIONEXPECTATION: return "ObservationInterpretationExpectation"; 564 case EXP: return "EXP"; 565 case UNE: return "UNE"; 566 case OBX: return "OBX"; 567 case REACTIVITYOBSERVATIONINTERPRETATION: return "ReactivityObservationInterpretation"; 568 case NR: return "NR"; 569 case RR: return "RR"; 570 case WR: return "WR"; 571 default: return "?"; 572 } 573 } 574 public String getSystem() { 575 return "http://hl7.org/fhir/v3/ObservationInterpretation"; 576 } 577 public String getDefinition() { 578 switch (this) { 579 case _GENETICOBSERVATIONINTERPRETATION: return "Codes that specify interpretation of genetic analysis, such as \"positive\", \"negative\", \"carrier\", \"responsive\", etc."; 580 case CAR: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder."; 581 case CARRIER: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code \"Carrier\" and to add \"CAR\" as the new active code representation for this concept."; 582 case _OBSERVATIONINTERPRETATIONCHANGE: return "Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed."; 583 case B: return "The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 584 case D: return "The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 585 case U: return "The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 586 case W: return "The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 587 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity."; 588 case LESS_THAN: return "The result is below the minimum detection limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Below analytical limit, low off scale."; 589 case GREATER_THAN: return "The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Above analytical limit, high off scale."; 590 case AC: return "A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 591 case IE: return "There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible.\r\n\n [Note: A MIC with \"IE\" and/or a comment may be reported (without an accompanying S, I or R-categorization).]"; 592 case QCF: return "A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 593 case TOX: return "A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 594 case _OBSERVATIONINTERPRETATIONNORMALITY: return "Interpretation of normality or degree of abnormality (including critical or \"alert\" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 595 case A: return "The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results.]"; 596 case AA: return "The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.]"; 597 case HH: return "The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Above upper panic limits."; 598 case LL: return "The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Below lower panic limits."; 599 case H: return "The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Above high normal"; 600 case H_: return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.]\r\n\n \n Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for \"Very high\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead."; 601 case HU: return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician."; 602 case L: return "The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Below low normal"; 603 case L_: return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.]\r\n\n \n Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for \"Very low\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead."; 604 case LU: return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician."; 605 case N: return "The result or observation value is within the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Applies to numeric or non-numeric results.]"; 606 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed."; 607 case I: return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.]\r\n\n [Note 3: This class also indicates a \"buffer zone,\" to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.]\r\n\n [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 608 case MS: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 609 case NS: return "A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible.\r\n\n NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. \r\n\n NOTE 2: For strains yielding results in the \"nonsusceptible\" category, organism identification and antimicrobial susceptibility test results should be confirmed.\r\n\n Synonym: decreased susceptibility."; 610 case R: return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) \nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 611 case SYNR: return "A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 612 case S: return "Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nSynonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 613 case SDD: return "A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates.\r\n\n Reference: CLSI document M44-A2 2009 \"Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition\" - page 2."; 614 case SYNS: return "A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 615 case VS: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 616 case EX: return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects.\nThese concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes.\nMembers of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 617 case HX: return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 618 case LX: return "The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported.\r\n\n Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 619 case HM: return "Hold for Medical Review\r\n\n \n Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 \"Interpretation Codes.\""; 620 case OBSERVATIONINTERPRETATIONDETECTION: return "Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the \"meaning\" of the quantitative value for the same observation."; 621 case IND: return "The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure.\r\n\n \n Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then \"indeterminate\" (i.e. \"cannot be determined\") is the appropriate response, not \"equivocal\"."; 622 case E: return "The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria."; 623 case NEG: return "An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.\r\n\n [Note: Negative does not necessarily imply the complete absence of the specified item.]"; 624 case ND: return "The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure."; 625 case POS: return "A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure."; 626 case DET: return "The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure."; 627 case OBSERVATIONINTERPRETATIONEXPECTATION: return "Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 628 case EXP: return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Expected\" (e.g., presence of drugs in a patient that is taking prescription medication for pain management)."; 629 case UNE: return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Unexpected\" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management)."; 630 case OBX: return "Interpretation qualifiers in separate OBX segments\r\n\n \n Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 \"Interpretation Codes.\""; 631 case REACTIVITYOBSERVATIONINTERPRETATION: return "Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test."; 632 case NR: return "An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent."; 633 case RR: return "A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test."; 634 case WR: return "A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test."; 635 default: return "?"; 636 } 637 } 638 public String getDisplay() { 639 switch (this) { 640 case _GENETICOBSERVATIONINTERPRETATION: return "GeneticObservationInterpretation"; 641 case CAR: return "Carrier"; 642 case CARRIER: return "Carrier"; 643 case _OBSERVATIONINTERPRETATIONCHANGE: return "ObservationInterpretationChange"; 644 case B: return "Better"; 645 case D: return "Significant change down"; 646 case U: return "Significant change up"; 647 case W: return "Worse"; 648 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "ObservationInterpretationExceptions"; 649 case LESS_THAN: return "Off scale low"; 650 case GREATER_THAN: return "Off scale high"; 651 case AC: return "Anti-complementary substances present"; 652 case IE: return "Insufficient evidence"; 653 case QCF: return "Quality control failure"; 654 case TOX: return "Cytotoxic substance present"; 655 case _OBSERVATIONINTERPRETATIONNORMALITY: return "ObservationInterpretationNormality"; 656 case A: return "Abnormal"; 657 case AA: return "Critical abnormal"; 658 case HH: return "Critical high"; 659 case LL: return "Critical low"; 660 case H: return "High"; 661 case H_: return "Significantly high"; 662 case HU: return "Significantly high"; 663 case L: return "Low"; 664 case L_: return "Significantly low"; 665 case LU: return "Significantly low"; 666 case N: return "Normal"; 667 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "ObservationInterpretationSusceptibility"; 668 case I: return "Intermediate"; 669 case MS: return "moderately susceptible"; 670 case NS: return "Non-susceptible"; 671 case R: return "Resistant"; 672 case SYNR: return "Synergy - resistant"; 673 case S: return "Susceptible"; 674 case SDD: return "Susceptible-dose dependent"; 675 case SYNS: return "Synergy - susceptible"; 676 case VS: return "very susceptible"; 677 case EX: return "outside threshold"; 678 case HX: return "above high threshold"; 679 case LX: return "below low threshold"; 680 case HM: return "Hold for Medical Review"; 681 case OBSERVATIONINTERPRETATIONDETECTION: return "ObservationInterpretationDetection"; 682 case IND: return "Indeterminate"; 683 case E: return "Equivocal"; 684 case NEG: return "Negative"; 685 case ND: return "Not detected"; 686 case POS: return "Positive"; 687 case DET: return "Detected"; 688 case OBSERVATIONINTERPRETATIONEXPECTATION: return "ObservationInterpretationExpectation"; 689 case EXP: return "Expected"; 690 case UNE: return "Unexpected"; 691 case OBX: return "Interpretation qualifiers in separate OBX segments"; 692 case REACTIVITYOBSERVATIONINTERPRETATION: return "ReactivityObservationInterpretation"; 693 case NR: return "Non-reactive"; 694 case RR: return "Reactive"; 695 case WR: return "Weakly reactive"; 696 default: return "?"; 697 } 698 } 699 700 701} 702